Double-Hit Large B Cell Lymphoma
Diffuse large B cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma (NHL), accounting for approximately 25% of NHL cases. It is a heterogeneous group of diseases. BCL2, BCL6, and MYC are the most frequent mutated genes in DLBCL. Double-hit lymphoma (DHL) is an aggressive form of DLBCL with an unmet treatment need, in which MYC rearrangement is present with either BCL2 or BCL6 rearrangement. Patients typically present with a rapidly growing mass with B symptoms. DHL has been linked to very poor outcomes when treated with RCHOP chemotherapy. Dual-expressor lymphoma is a form of DLBCL with overexpression of MYC and BCL2/BCL6. There is a paucity of prospective trials evaluating the treatment of DHL. Retrospective series suggest that more aggressive treatment regimens such as DA-EPOCH and hyper CVAD may be more efficacious. However, there remains a lack of consensus regarding optimal treatment for DHL. Further clinical trials, including novel agents, are needed for improvement in outcomes.
KeywordsDouble-hit lymphoma DLBCL MYC BCL2 BCL6
Compliance with Ethical Standards
Conflict of Interest
Yousef Khelfa, Yehuda Lebowicz, and Muhammad Omer Jamil declare that they have no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance
- 4.Hu S, Xu-Monette ZY, Tzankov A, et al. MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. Blood. 2013;121(20):4021–31. quiz 4250CrossRefPubMedPubMedCentralGoogle Scholar
- 18.Snuderl M, Kolman OK, Chen YB, et al. B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma. Am J Surg Pathol. 2010;34(3):327–40.CrossRefPubMedPubMedCentralGoogle Scholar
- 26.Kim S, Nam SJ, Kwon D, et al. MYC and BCL2 overexpression is associated with a higher class of Memorial Sloan-Kettering Cancer Center prognostic model and poor clinical outcome in primary diffuse large B-cell lymphoma of the central nervous system. BMC Cancer. 2016;16:363.CrossRefPubMedPubMedCentralGoogle Scholar
- 32.• Petrich AM, Gandhi M, Jovanovic B, et al. Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis. Blood. 2014;124(15):2354–61.Google Scholar
- 34.Landsburg DJ, Nasta SD, Svoboda J, Morrissette JJ, Schuster SJ. ‘Double-Hit’ cytogenetic status may not be predicted by baseline clinicopathological characteristics and is highly associated with overall survival in B cell lymphoma patients. Br J Haematol. 2014;166(3):369–74.CrossRefPubMedGoogle Scholar
- 35.McHugh DJ GP, Quinn J, Thornton P, Bird B, Sukor S, Fortune A, Parera K, Bacon E, Vandenberghe E, Flavin R, Grant C. Prevalence, clinico-pathological features and outcomes of ‘double-hit’ high-grade B-cell non-Hodgkins lymphoma (NHL): a single institution experience. Ann Oncol 2016; 27(suppl_6).Google Scholar
- 42.Kanungo A, et al. Lymphoid neoplasms associated with concurrent t (14; 18) and 8q24/c-MYC translocation generally have a poor prognosis. Mod Pathol. 2006;19(1):25.Google Scholar
- 43.Dunleavy K, Fanale M, LaCasce A, et al. Preliminary report of a multicenter prospective phase II study of DA-EPOCH-R in MYC-rearranged aggressive B-cell lymphoma. Blood. 2014;124:395.Google Scholar
- 44.• Cohen JB, Geyer SM, Lozanski G, et al. Complete response to induction therapy in patients with Myc-positive and double-hit non-Hodgkin lymphoma is associated with prolonged progression-free survival. Cancer. 2014;120(11):1677–85. Mainly describes the importance of first CR. CrossRefPubMedPubMedCentralGoogle Scholar
- 45.Nabhan C, Karrison T, Kline J, Cohen K, Bishop MR, Karmali R, et al. Prospective phase I multi-center trial incorporating lenalidomide (LEN) into dose-adjusted epoch plus rituximab (DA-EPOCH-R) in patients with double hit (DHL) or double expressing (DEL) lymphomas: final results. Blood. 2016;128:4191.Google Scholar
- 47.• Landsburg DJ, et al. Outcomes of patients with double-hit lymphoma who achieve first complete remission. J Clin Oncol 2017; JCO-2017.Google Scholar
- 48.Schuster SSJ, Dwivedy Nasta S, Chong EA, Winchell N, Landsburg DJ, Porter DL, June CH. Treatment with chimeric antigen receptor modified T cells directed against CD19 (CTL019) results in durable remissions in patients with relapsed or refractory diffuse large B cell lymphomas of germinal center and non-germinal center origin, “Double Hit” diffuse large b cell lymphomas, and transformed follicular to diffuse large B cell lymphomas. Web site. https://ash.confex.com/ash/2016/webprogram/Paper93934.html. Published 2016. Updated.
- 49.• Locke FL NS, Bartlett NL, et al. Primary results from ZUMA-1: a pivotal trial of axicabtagene ciloleucel (Axi-cel; KTE-C19) in patients with refractory aggressive non-Hodgkin lymphoma (NHL). 2017. Describes utility of CAR-19 in treatment of DLBCL in second line, this will likely be practice changing. Google Scholar
- 51.Dashnamoorthy R, Kandela I, Bhalla S, Mazar A, Evens AM. Evaluation of potency and the associated biology of the investigational proteasome inhibitor, ixazomib: redox, autophagic, and MAPK-dependent cell death in T-cell lymphoma (TCL) and hodgkin lymphoma (HL) cell lines and human lymphoma xenograft models. Blood. 2013;122:4407.Google Scholar
- 55.Davids MS, Seymour JF, Gerecitano JF, Kahl BS, Pagel JM, Wierda WG, et al. Phase I study of ABT-199 (GDC-0199) in patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL): responses observed in diffuse large B-cell (DLBCL) and follicular lymphoma (FL) at higher cohort doses. ASCO Meeting Abstr. 2014;32(15_suppl):8522.Google Scholar
- 58.Fanale MA, Hagemeister FB, Fayad L, Oki Y, Fowler N, Romaguera J, et al. A phase I trial of alisertib plus romidepsin for relapsed/refractory aggressive B- and T-cell lymphomas. Blood. 2014;124:1744.Google Scholar
- 61.Novero A, Ravella PM, Chen Y, Dous G, Liu D. Ibrutinib for B cell malignancies. Exp Hematol Oncol. 32014:4.Google Scholar